Welcome to our dedicated page for Gt Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on Gt Biopharma stock.
GT Biopharma Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company developing cancer therapeutics based on its proprietary TriKE natural killer (NK) cell engager platform. The GTBP news feed on Stock Titan aggregates company press releases, clinical updates, financial disclosures, and other public announcements so readers can follow how its NK cell–based programs progress over time.
News about GT Biopharma frequently centers on its lead clinical candidate GTB-3650, a second-generation TriKE being evaluated in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, including acute myeloid leukemia and high-risk myelodysplastic syndrome. Regular updates describe enrollment status across multiple cohorts, results of formal safety reviews, early observations on immune activation and NK cell expansion, and plans for subsequent dose levels within the study protocol.
Another recurring theme in GTBP news is the advancement of GTB-5550, a camelid nanobody-based TriKE targeting B7-H3–expressing solid tumors. Company announcements cover key regulatory milestones such as submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration and outline the design of a planned Phase 1 basket trial using subcutaneous dosing across several metastatic solid tumor cohorts.
Investors and observers will also find financial result releases, which summarize cash position, research and development spending related to GTB-3650 and GTB-5550, and general operating expenses, along with 8-K-linked updates on Nasdaq listing matters and capital structure changes. Conference participation notices and board or governance updates provide additional context on how GT Biopharma presents its NK cell engager strategy to the investment community.
By reviewing GTBP news on this page, readers can track clinical milestones, regulatory interactions, financing developments, and corporate actions that shape the company’s progress in NK cell–based immuno-oncology.
GT Biopharma, Inc. (NASDAQ: GTBP) announced that CEO Tony Cataldo will present at Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021. The summit is known for bringing together prestigious family offices and investors from over 30 countries, representing more than $4.5 trillion in wealth. GT Biopharma specializes in immuno-oncology therapeutics, utilizing its proprietary TriKE™ NK cell engager technology platform to enhance patients' natural killer cells for cancer treatment. For more information, visit gtbiopharma.com.
GT Biopharma announced interim clinical trial results of GTB-3550 TriKE™ at the Raymond James Health Innovation Conference. The Phase 1 trial targets high-risk MDS and refractory AML, with 57% of patients showing a notable reduction in cancer cell burden. Bone marrow blast levels decreased by up to 63.7%, and the treatment was well tolerated without significant side effects. Eleven patients completed treatment, and the trial will assess safety and recommend a Phase 2 dose, with results expected by September 2021.
GT Biopharma announced that Dr. Jeffrey S. Miller will update on the GTB-3550 TriKE™ Phase I trial at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. This session will accompany the Company's corporate update presentation. A live webcast will be available on GT Biopharma's website, with a replay archived for 30 days post-event. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE™ NK cell engager technology, developed in partnership with the University of Minnesota.
GT Biopharma, a clinical stage immuno-oncology company, will provide a corporate update at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. The presentation will showcase developments from their proprietary TriKE™ NK cell engager platform. A live webcast can be accessed via the company's website, with an archive available for 30 days post-event. GT Biopharma holds an exclusive agreement with the University of Minnesota for further therapy development.
GT Biopharma, Inc. (NASDAQ: GTBP) announced its inclusion in the Russell 2000 Index, effective June 28, 2021. This milestone reflects the company's progress in developing its TriKE™ NK cell engager technology. CEO Anthony J. Cataldo emphasized the importance of this recognition for enhancing visibility and growth potential. The Russell 2000 Index is significant for institutional investors, with approximately $9 trillion in assets benchmarked against Russell's U.S. indexes. The inclusion is expected to attract broader investment interest and support GT Biopharma's long-term objectives.
GT Biopharma, Inc. (NASDAQ: GTBP) announced a call with Dr. Jeffrey S. Miller on May 19, 2021, at 4:00 PM ET, to discuss interim results from its Phase I/II clinical trial of GTB-3550 TriKE™. Key highlights include a 63.7% reduction in bone marrow blast levels in patients with high-risk MDS and AML and a successful restoration of NK cell functions. Enrollment for the trial is ongoing, with the potential for accelerated approval based on new endpoints. A live webcast will be available for those interested.
GT Biopharma, Inc. (NASDAQ: GTBP) reported its Q1 2021 results on May 17, highlighting encouraging data from the Phase I/II trial of GTB-3550 TriKE™ for MDS and AML. The trial showed up to a 63.7% reduction in bone marrow blast levels with no cytokine release syndrome observed. The company completed a $28.7M financing boosting its cash position to $35M. R&D expenses rose to $1.6M, and general administrative expenses increased significantly to $27.3M due to stock-based compensation, resulting in a net loss of $29.7M.
GT Biopharma, Inc. (NASDAQ: GTBP) has commenced its Phase 2 clinical trial for the GTB-3550 TriKE™ monotherapy, focusing on high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The Phase 1 trial demonstrated a 63.7% reduction in bone marrow blast levels and restored NK cell function without requiring cell therapy. The Phase 2 trial aims to enhance efficacy and overall survival by enrolling patients with CD33 ≥50%. Additionally, GT Biopharma is developing three solid tumor TriKE™ candidates targeting various cancers, presenting significant market potential.
GT Biopharma, Inc. (NASDAQ: GTBP) announced the appointment of Gregory Berk, M.D. as Chief Medical Officer, effective April 26, 2021. Dr. Berk, who has over 30 years of oncology development experience, resigns from the Board of Directors to take on this role. Additionally, Jeffrey S. Miller, M.D. transitions from Consulting Chief Medical Officer to Consulting Chief Scientific Officer. The company aims to enhance its TriKE™ protein biologic platform, which targets solid tumors and hematologic cancers. Positive preliminary data for GTB-3550 in AML and MDS have been reported, highlighting a strong safety profile.
GT Biopharma reported its 2020 financial results, highlighting significant progress in its clinical pipeline, particularly with the GTB-3550 TriKE™ program targeting MDS and AML. The company achieved a successful NASDAQ listing and raised $28.7 million during its public offering. Financially, GT Biopharma's cash position increased to $5.3 million, up from $0.3 million in 2019, despite a net loss of $28.3 million for the year. The TriKE™ therapy demonstrates promising efficacy, with interim results showing a 63.7% reduction in cancer cell levels for treated patients.